It is important that the FDA proceeds with caution on drugs similar to Actos. With the science and technology we have at our disposal today, no one deserves to suffer because of dangerous pharmaceuticals.
St. Louis, MO (PRWEB) May 03, 2012
Attorneys at SL Chapman LLC, a law firm dedicated to representing victims with Actos complications, are not surprised by the Federal Drug Administration's recent denial of Takeda Pharmaceuticals' proposed replacement for Actos (intended to the treat type 2 diabetes) recently reported by Reuters (Reuters.com). In response to the FDA ruling, SL Chapman Actos attorney Rob Evola noted, "The ongoing FDA study of Actos complications has revealed the drug can cause an increased risk of bladder cancer and heart failure. It is important that the FDA proceeds with caution on drugs similar to Actos. With the science and technology we have at our disposal today, no one deserves to suffer because of dangerous pharmaceuticals."
This recent denial by the FDA is the second time the replacement drug has been rejected for use in the United States. The Actos lawyers at SL Chapman have developed a free Special Report outlining the dangers and complications of the drug. "7 Things You Must Know About Actos Complications" focuses on the known side effects of Actos (including heart failure and bladder cancer) and addresses readers’ concerns and answers questions regarding treatments. Report author and Founding Partner Brad Lakin added "Many countries outside of the US, including Germany and France, have already permanently banned Actos. The risk of complication is simply too high."
The team of Actos attorneys at SL Chapman LLC have secured over $700 million in verdicts, settlements, and other awards on behalf of their clients. The firm has offices in St. Louis, Phoenix, and Alton, Illinois. Partners at the firm have received accolades including Super Lawyers, Martindale-Hubbell +AV Preeminent rating, Top 100 Trial Lawyers and Million and Multi-Million Dollar Advocates Forums.
(References: Thompson Reuters - US Edition - http://www.reuters.com)